[Pubmed] Economic Burden of Myasthenia Gravis Exacerbation and Crisis from US Payer Perspective (P9-11.034)
Posté : 07 avr. 2025 12:00
Neurology. 2025 Apr 8;104(7_Supplement_1):1784. doi: 10.1212/WNL.0000000000208741. Epub 2025 Apr 7.
ABSTRACT
OBJECTIVE: To evaluate the impact of myasthenia gravis (MG) diagnosis, exacerbation, and crisis on healthcare costs.
BACKGROUND: MG is a rare autoimmune neuromuscular disease characterized by muscle weakness and fatigability. Little is known about the changes in healthcare costs before and after MG diagnosis, as well as the impact of clinical deterioration events on the healthcare costs among MG patients.
DESIGN/METHODS: Adults who had ≥1 inpatient or ≥2 outpatient claims (≥30 days apart) with MG diagnosis from 2017-2022, with ≥1 diagnosis provided by neurologist, and ≥12 months pre- and post-index (i.e., initial MG diagnosis) continuous enrollment were selected from the MarketScan® commercial and Medicare Supplemental databases. Patients with MG diagnosis during 12 months pre-index were excluded. MG exacerbation was defined as having a medical claim associated with MG acute exacerbation, the use of immunoglobulin or plasma exchange or MG-related hospitalization. MG crisis was defined as MG-related hospitalization associated with respiratory failure and endotracheal intubation/ventilation. Monthly all-cause healthcare costs before and after MG diagnosis were analyzed using restricted maximum likelihood controlling for age, gender, Charlson comorbidity index, and payer type.
RESULTS: A total of 891 newly diagnosed MG patients were identified [mean (±SD) age: 55.7 (±15.3) years; female: 52.7%; mean (±SD) Charlson comorbidity index: 1.2 (±1.6)]. All-cause costs increased by $1,163 per patient per month after MG diagnosis (P
Source: https://pubmed.ncbi.nlm.nih.gov/4019408 ... t9+e462414